ENTRADA THERAPEUTICS INC (TRDA) Fundamental Analysis & Valuation

NASDAQ:TRDA • US29384C1080

Current stock price

12.63 USD
-0.18 (-1.41%)
At close:
12.63 USD
0 (0%)
After Hours:

This TRDA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TRDA Profitability Analysis

1.1 Basic Checks

  • TRDA had negative earnings in the past year.
  • TRDA had a negative operating cash flow in the past year.
  • TRDA had negative earnings in 4 of the past 5 years.
  • TRDA had negative operating cash flow in 4 of the past 5 years.
TRDA Yearly Net Income VS EBIT VS OCF VS FCFTRDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M -100M -150M

1.2 Ratios

  • TRDA has a Return On Assets (-38.09%) which is comparable to the rest of the industry.
  • The Return On Equity of TRDA (-46.96%) is better than 64.15% of its industry peers.
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROIC N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
TRDA Yearly ROA, ROE, ROICTRDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TRDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRDA Yearly Profit, Operating, Gross MarginsTRDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. TRDA Health Analysis

2.1 Basic Checks

  • TRDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TRDA has more shares outstanding
  • TRDA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TRDA Yearly Shares OutstandingTRDA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
TRDA Yearly Total Debt VS Total AssetsTRDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 2.70 indicates that TRDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.70, TRDA is doing good in the industry, outperforming 67.05% of the companies in the same industry.
  • There is no outstanding debt for TRDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.7
ROIC/WACCN/A
WACC9.55%
TRDA Yearly LT Debt VS Equity VS FCFTRDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • TRDA has a Current Ratio of 12.53. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
  • TRDA has a Current ratio of 12.53. This is amongst the best in the industry. TRDA outperforms 86.24% of its industry peers.
  • TRDA has a Quick Ratio of 12.53. This indicates that TRDA is financially healthy and has no problem in meeting its short term obligations.
  • TRDA has a better Quick ratio (12.53) than 86.24% of its industry peers.
Industry RankSector Rank
Current Ratio 12.53
Quick Ratio 12.53
TRDA Yearly Current Assets VS Current LiabilitesTRDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TRDA Growth Analysis

3.1 Past

  • TRDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -281.15%.
  • TRDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.94%.
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%

3.2 Future

  • The Earnings Per Share is expected to grow by 6.49% on average over the next years.
  • TRDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.56% yearly.
EPS Next Y-15.39%
EPS Next 2Y-4.26%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y30.24%
Revenue Next 5Y46.56%

3.3 Evolution

TRDA Yearly Revenue VS EstimatesTRDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
TRDA Yearly EPS VS EstimatesTRDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5

More info and screens

Find the best growth stocksShow best growing peers

0

4. TRDA Valuation Analysis

4.1 Price/Earnings Ratio

  • TRDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TRDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRDA Price Earnings VS Forward Price EarningsTRDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRDA Per share dataTRDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.26%
EPS Next 3Y-0.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TRDA Dividend Analysis

5.1 Amount

  • TRDA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TRDA Fundamentals: All Metrics, Ratios and Statistics

ENTRADA THERAPEUTICS INC

NASDAQ:TRDA (4/24/2026, 4:14:35 PM)

After market: 12.63 0 (0%)

12.63

-0.18 (-1.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-07
Inst Owners74.23%
Inst Owner Change0%
Ins Owners1.09%
Ins Owner Change-0.61%
Market Cap483.48M
Revenue(TTM)25.42M
Net Income(TTM)-143.75M
Analysts86.15
Price Target20.91 (65.56%)
Short Float %2.74%
Short Ratio4.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.65%
Min EPS beat(2)-10.55%
Max EPS beat(2)19.86%
EPS beat(4)2
Avg EPS beat(4)9.2%
Min EPS beat(4)-20.31%
Max EPS beat(4)47.81%
EPS beat(8)6
Avg EPS beat(8)169.29%
EPS beat(12)7
Avg EPS beat(12)115.74%
EPS beat(16)8
Avg EPS beat(16)86.78%
Revenue beat(2)0
Avg Revenue beat(2)-88.39%
Min Revenue beat(2)-88.45%
Max Revenue beat(2)-88.33%
Revenue beat(4)1
Avg Revenue beat(4)-39.7%
Min Revenue beat(4)-88.45%
Max Revenue beat(4)98.17%
Revenue beat(8)5
Avg Revenue beat(8)58.11%
Revenue beat(12)8
Avg Revenue beat(12)73.98%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.81%
PT rev (3m)24.24%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.98%
EPS NY rev (1m)-1.03%
EPS NY rev (3m)5.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-81.45%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.02
P/FCF N/A
P/OCF N/A
P/B 1.58
P/tB 1.58
EV/EBITDA N/A
EPS(TTM)-3.46
EYN/A
EPS(NY)-3.99
Fwd EYN/A
FCF(TTM)-3.38
FCFYN/A
OCF(TTM)-3.36
OCFYN/A
SpS0.66
BVpS8
TBVpS8
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -38.09%
ROE -46.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-9.02%
ROA(5y)-16.26%
ROE(3y)-11.47%
ROE(5y)-19.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.42%
Cap/Sales 4.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.53
Quick Ratio 12.53
Altman-Z 2.7
F-Score3
WACC9.55%
ROIC/WACCN/A
Cap/Depr(3y)102.24%
Cap/Depr(5y)173.55%
Cap/Sales(3y)3.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-281.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3233.33%
EPS Next Y-15.39%
EPS Next 2Y-4.26%
EPS Next 3Y-0.93%
EPS Next 5Y6.49%
Revenue 1Y (TTM)-87.94%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-96.53%
Revenue Next Year14.56%
Revenue Next 2Y31.43%
Revenue Next 3Y30.24%
Revenue Next 5Y46.56%
EBIT growth 1Y-441.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.21%
EBIT Next 3Y-28.1%
EBIT Next 5YN/A
FCF growth 1Y-189.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-209.24%
OCF growth 3YN/A
OCF growth 5YN/A

ENTRADA THERAPEUTICS INC / TRDA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ENTRADA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TRDA.


What is the valuation status for TRDA stock?

ChartMill assigns a valuation rating of 0 / 10 to ENTRADA THERAPEUTICS INC (TRDA). This can be considered as Overvalued.


What is the profitability of TRDA stock?

ENTRADA THERAPEUTICS INC (TRDA) has a profitability rating of 1 / 10.


Can you provide the financial health for TRDA stock?

The financial health rating of ENTRADA THERAPEUTICS INC (TRDA) is 8 / 10.


What is the earnings growth outlook for ENTRADA THERAPEUTICS INC?

The Earnings per Share (EPS) of ENTRADA THERAPEUTICS INC (TRDA) is expected to decline by -15.39% in the next year.